#ice_t - Twitter Hashtag

7 days ago

Prior to the National #ICE_T Congress with @BilalAbidMD @msalmanfaisal @AtrashShebli #USMIRC #MedEd #MedTwitter @USMIRCNEWS #mmsm @US_HMC @Larvol @KUcancercenter @OpenMedKate @oncodaily

Abdallah81MD's tweet photo. Prior to the National #ICE_T Congress with @BilalAbidMD @msalmanfaisal @AtrashShebli
#USMIRC #MedEd #MedTwitter @USMIRCNEWS #mmsm @US_HMC @Larvol @KUcancercenter @OpenMedKate @oncodaily https://t.co/trWz4FWYj0

1

12

0

1

1K

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

11/ Bottom line: Even with: ✅ Triplets/quadruplets ✅ ASCT ✅ Maintenance 👉 HRMM still relapses early and frequently ⚡ The field must move toward: earlier immune redirection + smarter maintenance strategies #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #Myeloma

1

6

1

285

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

10/ Additional limitations: 🔬 Heterogeneous FISH panels across centers 📉 Possible under-detection of some cytogenetics 🧪 No MRD data 💊 Limited toxicity/dose modification data 🏥 Tertiary-center bias → may overestimate access to ASCT/novel agents #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #Myeloma

1

7

1

156

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

9/ ⚠️ Key Limitations (important for interpretation): 🔹 Retrospective design → selection bias 🔹 No standardized treatment protocols 🔹 15-year span → major era effect confounding 🔹 Short follow-up in modern era (Era 3) 🔹 No formal KM survival comparisons #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #Myeloma

1

6

1

2

112

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

8/ 🔮 Clinical implications: ➡️ Earlier quadruplet induction ➡️ Earlier BCMA-directed therapies (CAR-T / TCEs) ➡️ MRD-adapted strategies ➡️ Risk-adapted maintenance intensification #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #Myeloma

1

7

1

126

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

7/ Maintenance is evolving: 📉 Lenalidomide declining 📈 More PI+IMiD & CD38-based maintenance But… ⚠️ 22.4% progressed within 12 months 👉 Current maintenance strategies are insufficient for HRMM #ICE_T #MedEd #medtwitter #USMIRC @US @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #Myeloma

1

7

1

2

132

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

5/ Depth of response improves with intensification: Post-induction: ✅ ORR 83.9% ✅ ≥VGPR 56.1% Post-ASCT: 🔥 ≥VGPR 83.8% 🔥 CR/sCR 50.6% #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #Myeloma

Abdallah81MD's tweet photo. 5/ Depth of response improves with intensification:

Post-induction:
✅ ORR 83.9%
✅ ≥VGPR 56.1%

Post-ASCT:
🔥 ≥VGPR 83.8%
🔥 CR/sCR 50.6%

#ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #Myeloma https://t.co/JFI7z7vHHW

1

6

1

191

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

4/ ASCT remains central: 🚀 Overall: 75.1% 👥 <70 yrs: 83.9% 👥 ≥70 yrs: 43.2% 💡 Fit older pts achieved: ✅ ≥VGPR: 94.7% ✅ CR/sCR: 63.2% 👉 Age alone ≠ transplant exclusion #ICE_T #MedEd #medtwitter #USMIRC @U @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #Myeloma

1

6

1

156

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

2/ Frontline therapy evolved: ✅ Triplets still dominant (81%) → VRd most common 📈 Quadruplets increased: 3.2% ➝ 20.3% (Era 1 → Era 3) Reflects shift toward intensified upfront therapy. #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #myeloma

1

8

1

295

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

1/ HRMM defined by: 🧬 del(17p) 🧬 t(4;14), t(14;16), t(14;20) 🧬 gain/amp(1q), del(1p) ⚠️ 60% double-hit ⚠️ 7.3% triple-hit A biologically aggressive cohort. #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #myeloma

1

12

4

520

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

🧵 High-Risk Cytogenetic Multiple Myeloma remains one of the toughest therapeutic challenges in MM 🔬 We analyzed 205 HRMM patients across 6 U.S. centers over 15 years (2009–2024) to understand real-world practice patterns & outcomes. #MultipleMyeloma #mmsm #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS

Abdallah81MD's tweet photo. 🧵 High-Risk Cytogenetic Multiple Myeloma remains one of the toughest therapeutic challenges in MM 🔬

We analyzed 205 HRMM patients across 6 U.S. centers over 15 years (2009–2024) to understand real-world practice patterns & outcomes.

#MultipleMyeloma #mmsm #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS

3

24

12

13

7K

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

12/ Big picture takeaways ✅ Proof-of-concept: CAR-T can induce deep MRD(-) in SMM ⚠️ But: • Not practice-changing yet • Needs randomized trials + long-term data Bottom Line: I will not feel comfortable to treat HRSMM with Cilta-Cel!!! Even on a clinical trial #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #MYELOMA

1

6

1

0

227

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

11/ ⚠️ No QoL data • Hospitalization • Toxicity burden • Long-term function 👉 Critical in asymptomatic population #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #MYELOMA

1

7

1

0

138

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

10/ ⚠️ Neurotoxicity concerns • Novel NINTs (movement disorders) • Some persistent 🧠 In asymptomatic patients → BIG issue 👉 Tolerance threshold is much lower vs RRMM #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #MYELOMA

1

7

1

0

116

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

9/ ⚠️ Overtreatment risk SMM ≠ always destined to progress 💥 Treating all HR-SMM with CAR-T = • Cost • Toxicity • Resource burden 👉 Risk-benefit balance unclear #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #MYELOMA

1

6

1

0

109

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

8/ ⏳ Short follow-up (15 months) • SMM is a long disease course ❗ Key unanswered: • Are we curing disease? • Or just delaying progression? 👉 Durability remains UNKNOWN #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #MYELOMA

1

6

1

0

124

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

5/ 🧠 Neurotoxicity signal (important!) • Associated with ↑ CAR-T expansion & ALC • Some persistent grade 1 symptoms ⚠️ Raises concern for: • Parkinsonian features • Long-term neurologic risk 👉 Mechanism still unclear #ICE_T #MedEd #medtwitter #USMIRC @US @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #MYELOMA

1

5

1

115

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

Let’s get into business 4/ ⚠️ Toxicity profile • CRS: 100% (ALL grade 1–2) • Cytopenias: common but transient • NINTs (non-ICANS neurotoxicity): 35% 🧠 Cranial nerve palsies + movement disorders (!!) 👉 New neurotoxicity phenotype emerging #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #MYELOMA

1

5

1

0

137

Al-Ola A Abdallah MD (USMIRC)

@Abdallah81MD

7 months ago

2/ 👥 Study design • Phase 2, single-center • n = 20 treated patients • No induction, no bridging ❗ • Cilta-cel upfront 🎯 Primary: safety 🎯 Secondary: MRD, response #ICE_T #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @oncodaily @Larvol @USMIRCNEWS #mmsm #MYELOMA